

# NASDAQ: SBFM ☒ Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! ☒



DIGITAL ASSET DIRECT BY SUNSHINE BIOPHARMA INC.

Detroit, Michigan | November 23, 2022 11:20 AM Eastern Standard Time



Sunshine Biopharma (NASDAQ: SBFM) has entered into a collaboration agreement with one of North America's leading lipid nanoparticle ("LNP") formulation companies to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1! Learn more about this collaboration and its significance in this video! Sunshine Biopharma focuses on the research, development & commercialization of life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. Visit Sunshine Biopharma: <https://sunshinebiopharma.com/>  
<https://investors.sunshinebiopharma.com/>

**Contact Details**

Christine Petraglia - TraDigital IR

+1 917-633-8980

[investors@sunshinebiopharma.com](mailto:investors@sunshinebiopharma.com)

## Company Website

<https://sunshinebiopharma.com/>

## Tags

SUNSHINE BIOPHARMA

SBFM

BIOTECH

MEDICINE